GH Research (GHRS) Competitors $14.91 -0.12 (-0.80%) Closing price 07/3/2025 03:43 PM EasternExtended Trading$14.91 0.00 (0.00%) As of 07/3/2025 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GHRS vs. OGN, IBRX, MIRM, XENE, AMRX, BHC, GMTX, APLS, ARWR, and VCELShould you be buying GH Research stock or one of its competitors? The main competitors of GH Research include Organon & Co. (OGN), ImmunityBio (IBRX), Mirum Pharmaceuticals (MIRM), Xenon Pharmaceuticals (XENE), AMNEAL PHARMACEUTICALS (AMRX), Bausch Health Cos (BHC), Gemini Therapeutics (GMTX), Apellis Pharmaceuticals (APLS), Arrowhead Pharmaceuticals (ARWR), and Vericel (VCEL). These companies are all part of the "pharmaceutical products" industry. GH Research vs. Its Competitors Organon & Co. ImmunityBio Mirum Pharmaceuticals Xenon Pharmaceuticals AMNEAL PHARMACEUTICALS Bausch Health Cos Gemini Therapeutics Apellis Pharmaceuticals Arrowhead Pharmaceuticals Vericel Organon & Co. (NYSE:OGN) and GH Research (NASDAQ:GHRS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership. Does the media refer more to OGN or GHRS? In the previous week, Organon & Co. had 48 more articles in the media than GH Research. MarketBeat recorded 51 mentions for Organon & Co. and 3 mentions for GH Research. GH Research's average media sentiment score of 0.34 beat Organon & Co.'s score of 0.05 indicating that GH Research is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 3 Very Positive mention(s) 3 Positive mention(s) 39 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral GH Research 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of OGN or GHRS? 77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 56.9% of GH Research shares are owned by institutional investors. 2.0% of Organon & Co. shares are owned by company insiders. Comparatively, 41.6% of GH Research shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is OGN or GHRS more profitable? Organon & Co. has a net margin of 11.92% compared to GH Research's net margin of 0.00%. Organon & Co.'s return on equity of 227.43% beat GH Research's return on equity.Company Net Margins Return on Equity Return on Assets Organon & Co.11.92% 227.43% 7.34% GH Research N/A -19.20%-18.40% Which has more risk and volatility, OGN or GHRS? Organon & Co. has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, GH Research has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Which has higher earnings and valuation, OGN or GHRS? Organon & Co. has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganon & Co.$6.40B0.41$864M$2.883.50GH ResearchN/AN/A-$38.96M-$0.79-18.87 Do analysts recommend OGN or GHRS? Organon & Co. currently has a consensus price target of $18.00, suggesting a potential upside of 78.66%. GH Research has a consensus price target of $32.00, suggesting a potential upside of 114.62%. Given GH Research's stronger consensus rating and higher possible upside, analysts clearly believe GH Research is more favorable than Organon & Co..Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organon & Co. 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50GH Research 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryOrganon & Co. beats GH Research on 10 of the 16 factors compared between the two stocks. Get GH Research News Delivered to You Automatically Sign up to receive the latest news and ratings for GHRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GHRS vs. The Competition Export to ExcelMetricGH ResearchMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$781.98M$2.91B$5.53B$8.95BDividend YieldN/A2.42%5.38%4.09%P/E Ratio-18.8721.5627.4020.24Price / SalesN/A277.33417.66125.07Price / CashN/A41.9536.6357.47Price / Book4.337.518.085.67Net Income-$38.96M-$55.05M$3.16B$248.47M7 Day Performance19.86%4.59%2.81%3.29%1 Month Performance19.95%4.86%3.69%5.18%1 Year Performance23.73%5.82%35.30%21.35% GH Research Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GHRSGH Research1.9356 of 5 stars$14.91-0.8%$32.00+114.6%+23.7%$781.98MN/A-18.8710OGNOrganon & Co.4.8276 of 5 stars$9.82+0.7%$18.00+83.3%-50.4%$2.53B$6.40B2.694,000Trending NewsIBRXImmunityBio1.8886 of 5 stars$2.76-3.8%$12.25+343.8%-57.0%$2.53B$14.74M0.00590Negative NewsGap UpMIRMMirum Pharmaceuticals3.7125 of 5 stars$50.28-0.1%$65.50+30.3%+47.4%$2.49B$336.89M-31.23140News CoverageXENEXenon Pharmaceuticals3.2015 of 5 stars$31.49-1.7%$54.82+74.1%-3.9%$2.46B$9.43M-9.75210AMRXAMNEAL PHARMACEUTICALS3.2301 of 5 stars$7.91+1.2%$11.60+46.6%+26.8%$2.45B$2.79B13.258,100BHCBausch Health Cos3.1657 of 5 stars$6.11-1.1%$7.42+21.4%-2.8%$2.29B$9.63B-55.5520,700GMTXGemini TherapeuticsN/A$51.61+3.0%N/A+27.8%$2.24BN/A-51.6130High Trading VolumeAPLSApellis Pharmaceuticals4.5197 of 5 stars$17.62-0.4%$40.05+127.3%-49.2%$2.22B$781.37M-9.84770Trending NewsAnalyst ForecastAnalyst RevisionARWRArrowhead Pharmaceuticals3.9322 of 5 stars$15.51+1.2%$43.71+181.8%-33.1%$2.12B$3.55M-11.08400VCELVericel2.9247 of 5 stars$41.80-0.5%$61.14+46.3%-7.0%$2.12B$237.22M1,393.80300Positive News Related Companies and Tools Related Companies Organon & Co. Alternatives ImmunityBio Alternatives Mirum Pharmaceuticals Alternatives Xenon Pharmaceuticals Alternatives AMNEAL PHARMACEUTICALS Alternatives Bausch Health Cos Alternatives Gemini Therapeutics Alternatives Apellis Pharmaceuticals Alternatives Arrowhead Pharmaceuticals Alternatives Vericel Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GHRS) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GH Research PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share GH Research With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
